Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients

American Journal of Medicine

Volumn 104, Issue 1, 1998, Pages 48-55

  Keiser, Philip ^b   Rademacher, Steven ^a,b   Smith, James W ^a,b   Skiest, Daniel ^a,b   Vadde, Vinutha ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CLARITHROMYCIN; COTRIMOXAZOLE; DIDANOSINE; ETHAMBUTOL; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; RIFABUTIN; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BACTEREMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTEREMIA; BACTERIAL INFECTIONS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEUTROPENIA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031932298     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00269-6     Document Type: Article

References (41)

1. Farber BF, Lesser M, Kaplan MH, et al. Clinical significance of neutropenia in patients with the human immunodeficiency virus. Infect Control Hosp Epidemiol. 23:1991;429-434.
2. Baldwin GC, Fuller ND, Roberts R, et al. G-CSF and GM-CSF enhance neutrophil cytotoxicity toward HIV-infected cells. Blood. 74:1989;1673.
3. Roilides E, Walsh TJ, Pizzo PA, et al. G-CSF enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis. 163:1991;579-583.
4. Gilks CF, Brindle RJ, Otieno LS, et al. Life threatening bacteremia in HIV-1 seropositive adults admitted to a hospital in Nairobi, Kenya. Lancet. 336:1990;545.
5. Krumholz HM, Sande MA, Lo B. Community-acquired bacteremia in patients with AIDS, Clinical presentation, bacteriology, and outcome. Am J Med. 86:1989;776.
6. Rolson KV, Radentz S, Rodrigues S. Bacterial and fungal infections in patients with the acquired immunodeficiency syndrome. Cancer Dect Prevent. 14:1990;377.
7. Fitchenbaum C, Woeltje KF, Powderly W. Serious Pseudomonas aeruginosa infections in patients infected with HIV A case-control study . Clin Infect Dis. 1995;417-422.
8. Fitchenbaum C, Dunagan WC, Powderly W. Bactermia in hospitalized patients infected with the human immunodeficiency virus; a case control study of risk factors and outcome. JAIDS. 8:1995;51-57.
9. Northfelt D, Hanblet J, Aragon T, et al. Outcome of febrile neutropenia in patients with AIDS related non-Hodgkin's lymphoma. Blood. 76:(suppl 1):1990;491.
10. Shamak S, Bartlet JA. AZT-induced neutropenia are we too cautious? Lancet. 1:1989;91.
11. Keiser P, Higgs E, Smith JW. Neutropenia is associated with increased risk of bacterial infection in AIDS. Am J Med Sci. 312:1996;118-122.
12. Moore RD, Kerully JC, Chaission RE. Association between neutropenia and bacterial infections in AIDS. Arch Int Med. 155:1995;1965-1970.
13. Hermans P, Sommereijins B, Vancutsem N, Clumeck N. Neutropenia in HIV-positive patients: a case control study in a cohort of 1403 patients. Abstracts of 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; 1995.
14. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte-colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 29:1993;319-324.
15. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte-colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. NEJM. 315:1991;164-170.
16. Mauss S, Steinmetz HT, Willers H, et al. Low G-CSF serum levels in neutropenia but not in acute febrile infections in HIV-seropositive individuals; a causal role for G-CSF in HIV-associated neutropenia? Abstracts of 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995.
17. Kimura S, Matsuda J, Ikematsu, et al. Efficacy of rG-CSF on neutropenia in patient with AIDS. AIDS. 4:1990;1251.
18. van der Wouw PA, van Leeuwen R, van Oers, et al. Effects of rG-CSF on leukopenia in zidovudine treated patients with AIDS and AIDS-related complex, a phase I/II trial. Br J Haemato. 78:1991;319-324.
19. Jacobson MA, Donnell JJ, Porteous D, et al. Retinal and gastrointestinal disease due to CMV in patients with AIDS; prevalence, natural history, and response to gancilovir therapy. Q J Med. 254:1988;473.
20. Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant G-CSF and erythropoietin decreases hematologic toxicity from zidovudine. Blood. 77:1991;2109-2117.
21. Schneider MM, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus Dutch AIDS Treatment Group . J Infect Dis. 171:1995;1632-1636.
22. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection NIAID AIDS Clinical Trials Group . NEJM. 16:1995;332.
23. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group . Clin Infect Dis. 1995;S12-S31.
24. Moore RD, Chaisson RE. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS. 1995;1337-1342.
25. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. NEJM. 335:1996;384-391.
26. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection NIAID AIDS Clinical Trials Group . NEJM. 16:1995;700-705.
27. Friedman LA, Hidalgo J, Bartnyska LM, et al. The severity classification system for acquired immunodeficiency syndrome hospitalizations Association with survival after discharge and inpatient resource use . Med Care. 34:1996;178-184.
28. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. NEJM. 335:1996;392-398.
29. Saah AJ, Hoover DR, He Y, et al. Factors influencing survival after AIDS report from the Multicenter AIDS Cohort Study (MACS) . JAIDS. 7:1994;287-295.
30. Torres RA, Barr MR, McIntyre KI, et al. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease. Int J STD AIDS. 6:1995;19-26.
31. Smith MA, Brennessel DJ. Cytomegalovirus. Infect Dis Clin North Am. 8:1994;427-438.
32. Bowen EF, Wilson P, Atkins M, et al. Natural history of untreated cytomegalovirus retinitis. Lancet. 346:1995;1671-1673.
33. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis. 17:1993;837-842.
34. Navikas V, Link J, Persson C, et al. Increased mRNA expression of IL-6, IL 10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 9:1995;484-489.
35. Sher A, Gazzinelli RT, Oswald IP, et al. Role of T-cell derived cytokines in the down regulation of immune responses in parasitic and retroviral infection. Immunologic Reviews. 127:1992;183-204.
36. Clerici M, Shearer GM. Cellular immunity and a type 1 cytokine profile in protection against HIV infection and progression to AIDS. Research Immun. 145:1994;635-641.
37. Hartung T, Docke WD, Gantner F, et al. Effects of granulocyte-colony stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood. 85:1995;2482-2489.
38. Stricker RB, Goldberg B. Increase in lymphocyte subsets following treatment of HIV associated neutropenia with G-CSF. Blood V. 86:1995;2229.
39. Heinkelein M, Schneider-Schaulies J, Walker BD, Jassoy C. Inhibition of cytotoxicity and cytokine release release of CD8+ HIV specific cytotoxic T lymphocytes by pentoxiphylline. J Acquir Immune Defic Syn Hum Retrovirol. 10:1995;417-424.
40. Peterson PK, Gekker G, Bornemann M, et al. Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus. Antimicrob Agents Chemother. 39:1995;2807-2809.
41. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, et al. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 90:1993;5974-5978.